• Professor of Internal Medicine& Medical Oncology Jan 26, 2011 Marmara University Hospital
• Asso. Prof in Medical Oncology, September 2005
• Clinical Research Fellow, Investigation Drug Branch for Breast Cancer (IDBBC), European Organization for the Research and Treatment of Cancer (EORTC), Brussels, Belgium. April 2001 – April 2003, with DES “Dipom Etude Specialization” certificate, 2003
• Medical Oncology Fellowship, Marmara University Hospital, Department of Medical Oncology, Istanbul, 1999-2003
• Specialist Certificate, Internal Medicine, June1999.
• Chief Medical Resident, Marmara University Hospital, Istanbul, June-December 1998
• Visiting scholar, Saint Elizabeth’s Medical Center, Department of Medical Hematology/Oncology, Tufts University Boston, USA. Aug-Nov 1996
• Internal Medicine Residency, Marmara University Hospital, Istanbul, 1995-1999
• Neurology Residency, Haseki Hospital, Istanbul, 1994-1995
• Visiting scholar,Dudley Road Hospital, Birmingham, UK. Department of Diabetes, Endocrinology and Lipid Metabolism. July-Sept 1991
• Doctor of Medicine, Istanbul University, Cerrahpasa Medical School (Language of instruction: English) 1987-1993.
1. Atalay G, Eksioglu-Demiralp E, Akoglu T, Direskeneli H. The effects of nitric oxide donors and inhibitors on neutrophil functions in Behcet's disease. Clin Exp Rheumatol. 20(4 Suppl 26):S17-20 (2002).
2. Turhal NS, Gumus M, Atalay G, Aliustaoğlu M, Kabakas F, Karamanoğlu A, Sengoz M. Outpatient care in a Turkish university hospital. Journal of BUON 7:397-398 (2002)
3. Atalay G, Biganzoli L, Renard F, Paridaens R, Cufer T, Coleman R, Calvert AH, Gamucci T, Minisini A, Therasse P, Piccart MJ on behalf of the EORTC Breast Cancer and Early Clinical Studies Groups. Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomized metastatic breast cancer trials. Eur J Cancer 39, 2439-2449 (2003).
4. Turhal NS, Aliustaoğlu M,Gürses I, Gümüs M, Atalay G, Karamanoglu A, Sengoz M. Neoplastic diseases prevalence in a Turkish university hospital. Journal of BUON, 8:45-48 (2003).
5. Bonnefoi H, Biganzoli L, Mauriac L, Cufer T, Schaefer P, Atalay G, Piccart M. An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (CEX) as primary treatment for large operable or locally advanced/inflammatory breast cancer. Eur J Cancer 39:1277-83 (2003).
6. Atalay G, Dirix L, Biganzoli L, Beex L, Nooij M, Cameron D, Lohrisch C, Cufer T, Lobelle JP, Mattiaci MR, Piccart M, Paridaens R. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC trial 10951, “Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenapausal patients”. Ann Oncol 15: 211-7 (2004).
7. Yumuk PF, Gumus M, Ekenel M, Basaran G, Aliustaoglu M, Topal A, Turhal NS. Attitudetoward genetic testing for cancer risk in Istanbul. Genet Test. 2004 Summer; 8(2):169-73
8.Aliustaoglu M, Yumuk PF, Gumus M, Ekenel M, Bolukbas F, Bolukbas C, Mutlu N,
Basaran G, Avsar E, Turhal NS. D-dimer--can it be a marker for malignant gastric lesions?Acta Oncol. 2004;43(8):770-1.
Yumuk PF, Abacioglu U, Demir G, Cabuk D, Dane F, Gumus M, Ozguroglu M, Ekenel M, Basaran G, Turhal NS. Does the incidence of anal canal cancers differ in Moslem societies?Int J Colorectal Dis. 2005 Jan;20(1):76.
Basaran G, Agaoglu F, Basaran M. Doxorubicin, bleomycin, vinblastine, and dacarbazine alone in treatment of favorable, limited-stage Hodgkin's lymphoma: dowe really have robust data? J Clin Oncol. 2010 Sep 20;28(27)
Dane F, Yumuk PF, Gunduz F, Peker O, Basaran G, Turhal S. A case of primary breast mantle cell lymphoma with atypical relapse patterns and review of the literature. J BUON
Basaran G, Turhal NS, Cabuk D, Yurt N, Yurtseven G, Gumus M, Teomete M, Dane F, Yumuk PF. Weight gain after adjuvant chemotherapy in patients with early breast cancer in Istanbul Turkey. Med Oncol. 2010 Mar 20.
Basaran G, Cabuk D, Cağlar HB, Gulluoğlu B, Kaya H, Seber S, Korkmaz T, Telli F, Kocak M, Dane F, yumuk PF. Clinical outcome of breast cancer patients with N3a (>10 lymph nodes) disease: Has it changed over years? Med Oncol. 2010 Apr 14.
Yumuk PF, Kefeli U, Ceyhan B, Dane F, Eroglu BT, Gumus M, Cabuk D, Basaran G, Abacioglu U, Turhal NS. Pulmonary toxicity in patients receiving docetaxel chemotherapy. Med Oncol. 2009 Dec 25. [Epub ahead of print]
Dane F, Ozturk MA, Tecimer T, Atasoy BM, Cabuk D, Yumuk PF, Basaran G, Teomete M, Turhal NS. A case of Kikuchi-Fujimoto disease misdiagnosed as Hodgkin's lymphoma: the importance of second opinion. J BUON. 2009 Apr-Jun;14(2):309-11.
Kefeli U, Dane F, Yumuk PF, Karamanoglu A, Iyikesici S, Basaran G, Turhal NS. Prolonged interval in prophylactic heparin flushing for maintenance of subcutaneous implanted port care in patients with cancer. Eur J Cancer Care (Engl). 2009 Mar;18(2):191-4.
Kuscu MK, Dural U, Onen P, Yaşa Y, Yayla M, Basaran G, Turhal S, Bekiroğlu N. The association between individual attachment patterns, the perceived social support, and the psychological well-being of Turkish informal caregivers. Psychooncology. 2009 Sep;18(9):927-35.
Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Lück HJ, Mackey JR, Nabholtz JM, Paridaens R, Biganzoli L, Jassem J, Bontenbal M, Bonneterre J, Chan S, Basaran GA, Therasse P. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008 Apr 20;26(12):1987-92.
Piccart-Gebhart MJ, Burzykowski T, Buyse M, Sledge G, Carmichael J, Lück HJ, Mackey JR, Nabholtz JM, Paridaens R, Biganzoli L, Jassem J, Bontenbal M, Bonneterre J, Chan S, Basaran GA, Therasse P. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008 Apr 20;26(12):1980-6.
Yumuk PF, Dane F, Yumuk VD, Yazici D, Ege B, Bekiroglu N, Toprak A, Iyikesici S, Basaran G, Turhal NS. Impact of body mass index on cancer development. J BUON. 2008 Jan-Mar;13(1):55-9.
Cabuk D, Basaran G, Celikel C, Dane F, Yumuk PF, Iyikesici MS, Ekenel M, Turhal NS. Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: relationship with pathological factors and prognostic impact on survival. Oncology. 2007;72(1-2):111-7.
Ustuner Z, Basaran M, Dizdar Y, Agaoglu FY, Bilgic B, Sakar B, Basaran GA, Darendeliler E, Ozger H, Onat H, Bavbek S. Clinical outcome of rhabdomyosarcoma in adolescent and adult patients: single center experience from Turkey. Tohoku J Exp Med. 2007 Nov;213(3):221-9.
Pajk B, Cufer T, Canney P, Ellis P, Cameron D, Blot E, Vermorken J, Coleman R, Marreaud S, Bogaerts J, Basaran G, Piccart M. Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial. Breast. 2008 Apr;17(2):180-5. Epub 2007 Oct 31.
Celikel C, Yumuk PF, Basaran G, Yildizeli B, Kodalli N, Ahiskali R. Epithelioid hemangioendothelioma with multiple organ involvement. APMIS. 2007 Jul;115(7):881-8. Review.
Atasoy BM, Abacioglu U, Dane F, Ozgen Z, Yumuk PF, Ozden S, Akgun Z, Mayadagli A, Basaran G, Turhal S, Sengoz M. Concomitant administration of uracil-tegafur and leucovorin during adjuvant radiotherapy for locally advanced rectal cancer. J BUON. 2007 Apr-Jun;12(2):203-8.
Gumus M, Yumuk PF, Salepci T, Aliustaoglu M, Dane F, Ekenel M, Basaran G, Kaya H, Barisik N, Turhal NS. HPV DNA frequency and subset analysis in human breast cancer patients' normal and tumoral tissue samples. J Exp Clin Cancer Res. 2006 Dec;25(4):515-21.
Gumus M, Yumuk PF, Atalay G, Aliustaoglu M, Macunluoglu B, Dane F, Caglar H, Sengoz M, Turhal S. What is the optimal number of lymph nodes to be dissected in colorectal cancer surgery? Tumori. 2005 Mar-Apr;91(2):168-72.
Sakar B, Basaran G, Basaran M. Ewing's sarcoma of the rectum: are four cycles of chemotherapy enough? J Clin Oncol. 2005 Aug 20;23(24):5849-50; author reply 5850.
Basaran G, Basaran M, Onat H. Chemoradiotherapy for localized non-Hodgkin's lymphoma: lessons from old studies. J Clin Oncol. 2005 May 1;23(13):3161-2; author reply 3162-3.
Dane F, Akif Ozturk M, Gumus M, Guven A, Aliustaoglu M, Cabuk D, Teomete M, Basaran G, Fulden Yumuk P, Serdar Turhal N. Efficacy, safety and prognostic features of resected colon carcinoma treated in "real world" practice: a retrospective cohort-study. J BUON. 2011 Apr-Jun;16(2):257-64.
Saip P, Keskin S, Ozkan M, Kaplan MA, Aydogan F, Gonullu Demirag G, Uzunoglu
S, Engin H, Basaran G, Guler N, Uygun K, Demirkan B, Ozdemir F, Cubukcu E,
Salepci T, Cicin I. The access rate to diagnosis and treatment modalities in
breast cancer patients in Turkey; multicenter observational study. J BUON. 2011
Korkmaz T, Seber S, Okutur K, Basaran G, Yumuk F, Dane F, Ones T, Polat O,
Madenci OC, Demir G, Turhal NS. Serum thymidine kinase 1 levels correlates with
FDG uptake and prognosis in patients with non small cell lung cancer. Biomarkers.
Saip P, Eralp Y, Sen F, Karaca H, Ozkan M, Cetin B, Benekli M, Kucukoner M,
Isikdogan A, Un O, Basaran G, Onur H. Phase II study of lapatinib in combination
with vinorelbine in patients with HER2 positive recurrent or metastatic breast
cancer: a multicentric Turkish Oncology Group (TOG) trial. Breast. 2013
Oct;22(5):628-33. doi: 10.1016/j.breast.2013.07.048. Epub 2013 Aug 16.
Içli F, Altundağ K, Akbulut H, Paydaş S, Başaran G, Saip P, Doğu GG, Eralp Y,
Uslu R, Sevinç A, Onur H, Mandel NM, Sezgin C, Altınbaş M, Güler N, Işıkdoğan A,
Gökmen E, Uygun K, Ustüner Z, Yaren A, Demirkan B, Coşkun U, Ata A, Ozkan M,
Arican A. Nine weeks versus 1 year adjuvant trastuzumab in patients with early
breast cancer: an observational study by the Turkish Oncology Group (TOG). Breast
Cancer. 2013 Dec 12. [
Cabuk D, Basaran G, Teomete M, Dane F, Korkmaz T, Seber S, Telli F, Yumuk PF, Turhal S. Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities--single center experience. Asian Pac J Cancer Prev. 2014;15(1):117-22.
Iyikesici MS, Basaran G, Dane F, Ekenel M, Yumuk PF, Cabuk D, Teomete M,
Turhal NS. Associations between clinicopathological prognostic factors and pAkt,
pMAPK and topoisomerase II expression in breast cancer. Int J Clin Exp Med. 2014